To get a 'view into the innovation,' Servier began sponsoring programs at Cambridge's Lab Central in 2017, long before establishing its own R&D site in the US. This demonstrates a long-term corporate strategy of embedding in key ecosystems early to build relationships and monitor emerging science.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Eli Lilly is leveraging its massive GLP-1 drug revenue for a long-term strategic play. Instead of just acquiring single assets, the company is investing in global innovation hubs, supercomputing with NVIDIA, and incubators to build a sustainable innovation backbone, aiming to avoid typical patent cliff-driven downturns.

Strategic investors like Sanofi and AbbVie invest in early-stage biotechs not just for financial return, but to monitor disruptive technologies. This gives them a seat at the table to observe innovations that could render their own multi-billion dollar franchises obsolete in the next decade.

The merger of Novozymes and Chr. Hansen wasn't a typical cost-synergy play. They maintained their combined R&D spending ratio to proliferate their pipeline, using complementary technologies to solve problems neither company could address alone.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

Despite shedding over 22,000 jobs, large pharmaceutical companies are aggressively investing in external assets. This counterintuitive trend is driven by the urgent need to fill revenue gaps from a looming $300 billion patent cliff, signaling a major strategic shift from internal R&D to external innovation acquisition.

ProPhet was founded through Ion Labs, a venture studio created by AstraZeneca, Merck, Pfizer, and Teva. This model allows established pharmaceutical giants to identify acute internal challenges and recruit external talent to build dedicated startups aimed at solving them.

The widespread reduction in internal R&D spending does not signal a retreat from innovation. Instead, companies are redirecting capital towards external opportunities, evidenced by a recent surge in multi-billion dollar M&A 'bolt-on' deals. This represents a strategic shift from building in-house to buying external assets.